Mizuguchi T; Collod-Beroud G; Akiyama T; Abifadel M; Harada N; Morisaki T; Allard D; Varret M; Claustres M; Morisaki H; Ihara M; Kinoshita A; Yoshiura K; Junien C ...
This “endowment” can include recognized medical disorders such as height in Marfan Syndrome and delayed ... carrying capacity due to an inherited mutation in the erythropoietin receptor ...
The standard treatment for the connective tissue disorder Marfan's syndrome (MFS) is β-blockade, aimed at reducing aortic wall stress. Angiotensin II type 1 and 2 receptors (AT 1 and AT 2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback